Alerta

STABILIZED VACCINES

Resumen de: MX2025005412A

The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.

ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF II

Resumen de: US2025244325A1

The present disclosure relates to anti-SARS-COV-2 antibodies and uses thereof in detecting intact multimeric and/or intact trimeric severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike protein in a sample.

USE OF SHENLING BAIZHU IN PREPARING MEDICAMENT FOR TREATING POST-HEALING SEQUELAE OF NOVEL CORONAVIRUS INFECTED PERSON

Resumen de: AU2023412582A1

Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of short of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.

CORONAVIRUS VACCINE

Resumen de: US2025242059A1

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3

Resumen de: US2025243282A1

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

COMPOSITION FOR PREVENTING OR TREATING CHEMOSENSORY DISORDER

Resumen de: AU2024251861A1

The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, the composition including lactic acid bacteria. The chemosensory disorder may be a chemosensory disorder that occurs after SARS-CoV-2 virus infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect for a chemosensory disorder, and in that pharmaceuticals or foodstuffs that are safe for mammals, including humans, can be provided.

METHODS OF ANALYZING SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AND USES THEREOF

Resumen de: US2025244338A1

The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.

PEPTIDE FOR PREVENTION OR TREATMENT OF COVID-19

Resumen de: US2025241978A1

A peptide for prevention and treatment of COVID-19 in a patient, wherein the peptide consists of 7-17 amino acids and includes the hexamer TX1EX2X3E, wherein X1, X2 and X3 can be any natural or non-natural amino acid, and wherein the peptide does not exhibit TNF-receptor-binding activity. Suitable peptides include solnatide (cyclo-CGQRETPEGAEAKPWYC).

BLOOD BIOMARKERS IN LONG-COVID-19

Resumen de: US2025244326A1

A method of diagnosing long-COVID in a subject, the method comprising: (a) measuring the level of one or more biomarkers in a test sample obtained from the subject, and (b) comparing the level of the one or more biomarkers in the test sample with a healthy control and/or an acute COVID-19 reference level value of said one or more biomarkers, wherein an increase in the level of the one or more biomarkers in the test sample relative to the healthy control and/or acute COVID-19 reference level value of said one or more biomarkers is indicative of long-COVID diagnosis, and wherein the one or more biomarkers are selected from Table 5. In one embodiment, the one or more biomarkers include ANG-1, P-Sel and MMP-1. A method of treating long-COVID comprising administering to a subject one or more of the biomarkers are selected from Table 5.

VIRUS-LIKE PARTICLE STABLY EXPRESSED BY ANIMAL CELLS AS VACCINE ANTIGEN AGAINST COVID-19 AND INFLUENZA VIRUS

Resumen de: US2025242013A1

The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.

NLRP3 INFLAMMASOME INHIBITORS AND COMPOSITIONS AND USES THEREOF

Resumen de: US2025243172A1

NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, acute myocardial infarction, heart failure, arthritis, diabetes, gout, COVID-19, and autoinflammatory diseases.

PROTECTIVE APPARATUSES FOR MINIMIZING RISK OF TRANSMISSION OF INFECTION AND ASSOCIATED SYSTEMS

Resumen de: EP4591823A2

Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.

Method for manufacturing SARS-CoV-2 autologous vaccine using recombinant SARS-CoV-2 lentiviral vector

Resumen de: KR20250115147A

본 발명은 재조합 SARS-CoV-2 렌티바이러스 벡터를 이용한 SARS-CoV-2 자가면역 백신의 제조방법에 관한 것으로, 구체적으로 본 발명은 SARS-CoV-2 바이러스의 항원 단백질을 암호화하는 폴리뉴클레오티드를 포함하는 수지상 세포에서 면역원성 항원 단백질의 발현을 유도하기 위한 재조합 렌티바이러스 벡터, 상기 본 발명의 재조합 렌티바이러스 벡터를 수지상 세포에 형질도입하는 단계를 포함하는, 수지상 세포 기반의 SARS-CoV-2 바이러스 감염증 예방용 백신 조성물의 제조방법 및 상기 방법으로 제조된 SARS-CoV-2 바이러스 감염증 예방용 백신 조성물에 관한 것이다.

CORONAVIRUS VACCINE

Resumen de: ZA202406805B

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

PHARMACEUTICAL COMPOSITION COMPRISING CHLOROQUINE AND USES THEREOF

Resumen de: ZA202304380B

The present invention relates to pharmaceutical compositions comprising chloroquine and uses thereof. More specifically, the invention relates to a pharmaceutical composition comprising chloroquine or pharmaceutically acceptable salts thereof for use in the treatment or prevention of a viral lung infection, preferably caused by Betacoronavirus, including but not limited to 2019-nCoV (coronavirus), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV), wherein the pharmaceutical composition is administered by inhalation. The present invention provides an improved delivery into the lungs of a subject with minimum systemic exposure.

ANTIVIRAL SIRNA THERAPEUTIC FOR SARS-COV-2

Resumen de: AU2023347083A1

This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.

METHOD OF DETECTING SARS-COV IN A SAMPLE

Resumen de: US2025236920A1

A method of detecting SARS-CoV-2 includes contacting a sample with a primer set and reverse transcription loop-mediated isothermal amplification (RT-LAMP) reagents, which includes calcein, to form a reaction mixture, and amplifying the cDNA by incubating the reaction mixture to amplify the target sequence of the SARS-CoV-2 nucleic acid sequence in the sample. The sample is further assayed with an assay to detect the amplified target sequence of the SARS-CoV-2 nucleic acid sequence, and thereby to detect SARS-CoV-2 in the sample.

BROADLY SARS-COV-2 NEUTRALIZING MONOCLONAL ANTIBODIES AND USES THEREOF

Resumen de: WO2025153707A1

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

PREDICTIVE MODEL FOR VARIANTS ASSOCIATED WITH DRUG RESISTANCE AND THERANOSTIC APPLICATIONS THEREOF

Resumen de: US2025237642A1

Methods for predicting mutations in viruses, such as Coronaviruses, upon exposure to antiviral drugs, are disclosed. Mutated, non-naturally occurring viruses including those mutations, and methods of treatment with drugs that remain effective against the mutated viruses, are disclosed. These predictive methods can be useful in properly treating Covid patients with small molecule antiviral compounds that are effective against the particular SARS-COV-2 variant infecting the patient.

SARS-CoV-2 VACCINE COMPOSITIONS

Resumen de: US2025235529A1

The present disclosure provides compositions of adjuvanted SARS-CoV-2 vaccines and their use to prevent and manage Covid-19 infection, including host hyperinflammatory responses to infection, including long term symptoms associated with Covid infection.

Anti COVID-19 Therapies targeting nucleocapsid and spike proteins

Resumen de: US2025235530A1

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

NOVEL CRISPR/CAS13 SYSTEMS AND USES THEREOF

Resumen de: US2025236912A1

The present invention relates to the field of RNA editing using novel Cast 3 polypeptides in a CRISPR/Cas13 system. The novel Cast 3 polypeptides have collateral, or ‘trans’ cleavage activity and can be utilised in a nucleic acid detection systems, such as a Cast 3 SARS-CoV-2-based detection assay.

BROADLY SARS-COV-2 NEUTRALIZING MONOCLONAL ANTIBODIES AND USES THEREOF

Resumen de: WO2025153835A1

The invention relates to antibodies against Severe Acute Respiratory Syndrome -related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

NEW METHOD TO DIAGNOSE INFLAMMATORY DISEASES

Resumen de: US2025236913A1

The present invention relates to the diagnostic of inflammatory diseases. The inventors described methods using NET biomarkers as diagnostic biomarkers for inflammatory diseases. COVID-19, Lupus or mCRC are used here as illustrative models for investigating an inflammatory disease. Examples in highlighting variation of the respective correlation of NET biomarkers in this invention rely on the determination of the NET main constituents: (i), DNA as determined by examining the amount of circulating DNA (cirDNA) that corresponds to the amount of NET as being degradation by-products that are released into the circulation; (ii) NE; and (iii), MPO; as well as the detection of a blood compound being indirectly associated to NET formation like the anti-cardiolipin auto-antibody. The invention provides threshold values of NE, MPO, cir-nDNA, and cir-mtDNA blood concentrations and of MNR that can be combined to diagnose/screen individuals. Thus the invention relates to a method for diagnosing a subject for an inflammatory disease comprising the steps of i) determining in a sample obtained from the subject the level of at least one marker selected in the group consisting in NET protein markers, cir-nDNA, cir-mtDNA and/or a cir-DNA fragmentation index.

METHODS OF TREATING FIBROSIS

Nº publicación: US2025235452A1 24/07/2025

Solicitante:

ENDEAVOR BIOMEDICINES INC [US]
Endeavor BioMedicines, Inc

Resumen de: US2025235452A1

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.